Delivery of antihuman African trypanosomiasis drugs across the blood-brain and blood-CSF barriers

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)


Human African trypanosomiasis (HAT or sleeping sickness) is a potentially fatal disease caused by the parasite, Trypanosoma brucei sp. The parasites are transmitted by the bite of insect vectors belonging to the genus Glossina (tsetse flies) and display a life cycle strategy that is equally spread between human and insect hosts. T.b. gambiense is found in western and central Africa whereas, T.b. rhodesiense is found in eastern and southern Africa.The disease has two clinical stages: a blood stage after the bite of an infected tsetse fly, followed by a central nervous system (CNS) stage where the parasite penetrates the brain; causing death if left untreated. The blood-brain barrier (BBB) makes the CNS stage difficult to treat because it prevents 98% of all known compounds from entering the brain, including some anti-HAT drugs. Those that do enter the brain are toxic compounds in their own right and have serious side effects.There are only a few drugs available to treat HAT and those that do are stage specific. This review summarizes the incidence, diagnosis, and treatment of HAT and provides a close examination of the BBB transport of anti-HAT drugs and an overview of the latest drugs in development.
Original languageEnglish
Pages (from-to)245-275
Number of pages31
JournalAdvances in Pharmacology
Publication statusPublished - 2014


  • Blood-brain barrier
  • Breast cancer resistance protein
  • Eflornithine
  • Human African trypanosomiasis
  • Melarsoprol
  • Multidrug resistance-associated protein
  • Nifurtumox
  • P-glycoprotein
  • Pentamidine
  • Suramin


Dive into the research topics of 'Delivery of antihuman African trypanosomiasis drugs across the blood-brain and blood-CSF barriers'. Together they form a unique fingerprint.

Cite this